Equities analysts predict that Sierra Oncology Inc (NASDAQ:SRRA) will report earnings per share of ($0.21) for the current quarter, according to Zacks. Zero analysts have made estimates for Sierra Oncology’s earnings. The highest EPS estimate is ($0.17) and the lowest is ($0.23). Sierra Oncology posted earnings of ($0.20) per share during the same quarter last year, which suggests a negative year-over-year growth rate of 5%. The business is expected to issue its next earnings results on Tuesday, February 26th.
According to Zacks, analysts expect that Sierra Oncology will report full-year earnings of ($0.77) per share for the current financial year, with EPS estimates ranging from ($0.80) to ($0.73). For the next fiscal year, analysts anticipate that the company will post earnings of ($0.80) per share, with EPS estimates ranging from ($0.95) to ($0.66). Zacks’ earnings per share averages are a mean average based on a survey of sell-side research analysts that cover Sierra Oncology.
Sierra Oncology (NASDAQ:SRRA) last announced its earnings results on Thursday, November 8th. The biotechnology company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($0.03).
Several equities research analysts have issued reports on the stock. ValuEngine raised shares of Sierra Oncology from a “hold” rating to a “buy” rating in a research note on Thursday, November 1st. Zacks Investment Research cut shares of Sierra Oncology from a “hold” rating to a “sell” rating in a research note on Thursday, October 4th.
Institutional investors and hedge funds have recently made changes to their positions in the business. Morgan Stanley raised its holdings in shares of Sierra Oncology by 11.3% during the 3rd quarter. Morgan Stanley now owns 992,516 shares of the biotechnology company’s stock worth $1,687,000 after acquiring an additional 100,709 shares during the period. Prosight Management LP raised its holdings in shares of Sierra Oncology by 50.6% during the 3rd quarter. Prosight Management LP now owns 2,720,089 shares of the biotechnology company’s stock worth $4,624,000 after acquiring an additional 913,527 shares during the period. Algert Global LLC raised its holdings in shares of Sierra Oncology by 173.8% during the 3rd quarter. Algert Global LLC now owns 394,258 shares of the biotechnology company’s stock worth $670,000 after acquiring an additional 250,267 shares during the period. Renaissance Technologies LLC raised its holdings in shares of Sierra Oncology by 27.5% during the 3rd quarter. Renaissance Technologies LLC now owns 2,252,244 shares of the biotechnology company’s stock worth $3,829,000 after acquiring an additional 485,344 shares during the period. Finally, Citadel Advisors LLC raised its holdings in shares of Sierra Oncology by 42.7% during the 3rd quarter. Citadel Advisors LLC now owns 1,832,042 shares of the biotechnology company’s stock worth $3,114,000 after acquiring an additional 548,591 shares during the period. 60.50% of the stock is currently owned by institutional investors.
SRRA traded up $0.03 on Monday, hitting $1.55. 7,905 shares of the company’s stock were exchanged, compared to its average volume of 522,135. Sierra Oncology has a fifty-two week low of $1.48 and a fifty-two week high of $4.09. The company has a quick ratio of 14.68, a current ratio of 14.68 and a debt-to-equity ratio of 0.05. The stock has a market cap of $113.04 million, a PE ratio of -1.85 and a beta of 1.72.
About Sierra Oncology
Sierra Oncology, Inc, a clinical stage drug development company, researches, develops, and commercializes DNA Damage Response (DDR) therapeutics for the treatment of patients with cancer in the United States and internationally. The company's lead drug candidate is SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1, which is in Phase 1 clinical trial to treat patients with advanced cancer.
Featured Article: Why do companies engage in swaps?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sierra Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sierra Oncology and related companies with MarketBeat.com's FREE daily email newsletter.